Lamotrigina [Spanish] en es it fr

Lamotrigina [Spanish] Brand names, Lamotrigina [Spanish] Analogs

Lamotrigina [Spanish] Brand Names Mixture

  • No information avaliable

Lamotrigina [Spanish] Chemical_Formula


Lamotrigina [Spanish] RX_link

Lamotrigina [Spanish] fda sheet

Lamotrigina_[Spanish] FDA

Lamotrigina [Spanish] msds (material safety sheet)

Lamotrigina_[Spanish] MSDS

Lamotrigina [Spanish] Synthesis Reference

M. G. Baxter et al., Eur. pat. Appl. 21,121 (1981 to Wellcome Foundation); D. A. Sawyer et al., U.S. pat. 4,602,017 (1986)

Lamotrigina [Spanish] Molecular Weight

256.091 g/mol

Lamotrigina [Spanish] Melting Point

216-218 oC (uncorr)

Lamotrigina [Spanish] H2O Solubility

No information avaliable

Lamotrigina [Spanish] State


Lamotrigina [Spanish] LogP


Lamotrigina [Spanish] Dosage Forms

Tablet; Chewable

Lamotrigina [Spanish] Indication

For the adjunctive treatment of partial seizures in epilepsy and generalized seizures of Lennox-Gastaut syndrome; For the maintenance treatment of Bipolar I Disorder

Lamotrigina [Spanish] Pharmacology

Lamotrigine, an antiepileptic drug (AED) of the phenyltriazine class, is chemically unrelated to existing antiepileptic drugs. Lamotrigine is also used in the treatment of depression and bipolar disorder. Lamotrigine is thought to exert its anticonvulsant effect by stabilizing presynaptic neuronal membranes. Lamotrigine inhibits sodium currents by selectively binding to the inactivated state of the sodium channel and subsequently suppresses the release of the excilatory amino acid, glutamate.

Lamotrigina [Spanish] Absorption


Lamotrigina [Spanish] side effects and Toxicity

LD50=250 (mg/kg) (in rat, mice); LD50>640 orally (mg/kg) (in rat, mice) (Sawyer); Decreased level of consciousness, coma, delayed heartbeat, increased seizures, lack of coordination, rolling eyeballs

Lamotrigina [Spanish] Patient Information

Lamotrigina [Spanish] Organisms Affected

Humans and other mammals